Allogene Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Allogene Therapeutics şirketinin toplam hissedar öz sermayesi $463.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $589.1M ve $125.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$291.56m
Eşitlik	US$463.75m
Toplam yükümlülükler	US$125.37m
Toplam varlıklar	US$589.12m

Son finansal sağlık güncellemeleri

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?

Nov 22

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Mar 01

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Jun 09

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Feb 22

Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Oct 27

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Jul 14

Recent updates

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

May 30

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Apr 01

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Mar 01

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Jun 09

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Feb 22

Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Oct 27

Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate

Oct 06

An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued

Sep 22

Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A

Sep 13

Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M

Aug 09

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Jul 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ALLO 'nin kısa vadeli varlıkları ( $304.4M ) kısa vadeli yükümlülüklerini ( $32.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: ALLO şirketinin kısa vadeli varlıkları ( $304.4M ) uzun vadeli yükümlülüklerini ( $92.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ALLO borçsuzdur.

Borcun Azaltılması: ALLO son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ALLO şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ALLO serbest nakit akışı her yıl % 11.2 1.3 yıl yetecek nakit akışına sahip olacaktır.

Allogene Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Recent updates

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Consensus revenue estimates decrease by 96%, EPS upgraded

Allogene Therapeutics, Inc. Reports Unaudited Impairment Charges for the Third Quarter Ended September 30, 2024

Allogene Therapeutics, Inc. Reports Unaudited Impairment Charges for the Third Quarter Ended September 30, 2024

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.37 loss in 3Q 2023)

Allogene Therapeutics, Inc. Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Executive VP & CFO notifies of intention to sell stock

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Senior VP notifies of intention to sell stock

Consensus revenue estimates decrease by 58%, EPS upgraded

Price target decreased by 17% to US$9.62

Allogene Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Allogene Therapeutics Inc. Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel as Part of First Line Treatment for Patients with Large B-Cell Lymphoma

Allogene Therapeutics, Inc. Announces Executive Changes

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

Consensus revenue estimates increase by 2,115%

Allogene Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $110.000002 million.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Allogene Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Consensus revenue estimates decrease by 43%, EPS upgraded

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Allogene Therapeutics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Insider notifies of intention to sell stock

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of Car T Led by ALPHA3

Consensus revenue estimates increase by 10%

Allogene Therapeutics, Inc. Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647

Price target decreased by 8.5% to US$13.13

Consensus revenue estimates increase by 23%

Price target decreased by 14% to US$14.36

Allogene Therapeutics, Inc. Presents Preclinical Data on Next Generation Cloak and Dagger Technologies At the Society for Immunotherapy of Cancer Annual Meeting

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Allogene Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Allogene Therapeutics, Inc. Appoints Geoffrey Parker as Executive Vice President

Consensus revenue estimates increase by 34%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Allogene Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

New minor risk - Share price stability

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

Allogene Therapeutics, Inc. Announces Resignation of Eric Schmidt from Principal Financial Officer and Principal Accounting Officer, Effective from August 2, 2023

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Allogene Therapeutics, Inc. Presents Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials of ALLO-501/501A in Patients with Relapsed/Refractory Large B-Cell Lymphoma at American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

Consensus revenue estimates increase by 96%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 99%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Allogene Therapeutics, Inc. Presents Data on Dagger, a Next Generation AlloCAR T Platform Technology

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

Price target decreased by 7.4% to US$22.00

Price target decreased to US$23.00

Allogene Appoints Zachary J. Roberts as Executive Vice President of Research & Development

Price target decreased to US$24.06

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

Price target decreased to US$25.00

Insufficient new directors

Consensus revenue estimates increase by 26%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans